within Pharmacolibrary.Drugs.ATC.B;

model B01AC27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.49,
    Cl             = 0.5766666666666667,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.0115,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008833333333333334,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Selexipag is an oral selective IP prostacyclin receptor agonist used for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization. It is approved for use in adults and is considered a first-in-class medication acting on the prostacyclin pathway.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adults after single oral dose administration.</p><h4>References</h4><ol><li><p>Kaufmann, P, et al., &amp; Mukai, H (2015). Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. <i>American journal of cardiovascular drugs : drugs, devices, and other interventions</i> 15(3) 195–203. DOI:<a href=&quot;https://doi.org/10.1007/s40256-015-0117-4&quot;>10.1007/s40256-015-0117-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25850750/&quot;>https://pubmed.ncbi.nlm.nih.gov/25850750</a></p></li><li><p>Kaufmann, P, et al., &amp; Dingemanse, J (2015). Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. <i>British journal of clinical pharmacology</i> 80(4) 670–677. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12650&quot;>10.1111/bcp.12650</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25851691/&quot;>https://pubmed.ncbi.nlm.nih.gov/25851691</a></p></li><li><p>Kaufmann, P, et al., &amp; Dingemanse, J (2016). Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. <i>British journal of clinical pharmacology</i> 82(2) 369–379. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12963&quot;>10.1111/bcp.12963</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27062188/&quot;>https://pubmed.ncbi.nlm.nih.gov/27062188</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC27;
